There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

WeightWatchers will begin selling compounded alternatives to certain weight-loss drugs that are experiencing shortages. Why it matters: Federal law allows companies to sell compounded versions of drugs that are on the FDA's shortages list — which has led to a surge of copycats to the newly popular class of GLP-1 injections.

Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the Congressional Budget Office (CBO). In its estimates released Tuesday, CBO

Explore how pharmaceutical researchers are fueling weight loss drug development using biospecimens to unlock the underlying mechanisms of obesity.

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a growing number say they’re open to covering GLP-1 drugs, they’re still in the minority. Some 62% of the firms surveyed said they are “not likely” to begin coverage in the coming year.

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly's (NYSE:LLY) diabetes therapy Mounjaro and weight loss therapy Zepbound,